Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In

NCT04439006 is registered in ClinicalTrials.gov with Jennifer Woyach as lead sponsor.

NCT NCT04439006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04439006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
Lead sponsor
Jennifer Woyach
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2020
Completion date
September 20, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aplastic anemia, hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm, monoclonal b-cell lymphocytosis, monoclonal gammopathy of undetermined significance, myelodysplastic syndrome, symptomatic covid-19 infection laboratory-confirmed